February 16th 2024
The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
TLR9 Agent Triggers Durable Response in Metastatic Melanoma
November 10th 2019The use of CMP-001, an intratumoral toll-like receptor 9 agonist, is capable of triggering durable responses when used in combination with pembrolizumab for patients with PD-1 resistant metastatic melanoma according to results from a phase Ib study presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
Wealth of Options Available for Adjuvant Melanoma Therapy
November 8th 2019Immunotherapies and targeted therapies have greatly impacted the treatment of advanced melanoma and are beginning to make their way into earlier settings, with FDA approvals for adjuvant therapies and studies ongoing in the neoadjuvant space, according to a presentation by Jeffrey S. Weber, MD, PhD, at the <em>37th Annual</em> CFS.
Read More
Pavlick Covers Research in BRAF Wild-Type Metastatic Melanoma
October 24th 2019During a <em>Targeted Oncology </em>live case-based peer perspectives live discussion, Anna C. Pavlick, DO, MS, explained to a group of physicians best practices for the diagnosis and management of patients with metastatic melanoma. Pavlick, discussed treatment options between immunotherapy and targeted therapy based on the case scenario of a patient with <em>BRAF </em>wild-type metastatic melanoma.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma
October 3rd 2019Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with <em>BRAF V600</em>–mutant unresectable or metastatic melanoma.
Watch
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents
September 27th 2019“New therapies have increased the median survival for advanced-stage melanoma from approximately 9 months before 2011 to at least 2 years, based on [data from] clinical trials,” Elizabeth Ward, PhD, and colleagues wrote about their report on cancer burden in younger patients.
Read More
Annual Hematology Meeting Cochair Encourages Embracing of CAR T-Cell Therapy
September 24th 2019Now in it 24th year, the annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma, hosted by Physicians’ Education Resource, LLC, continues to bring significant advances in hematology to the forefront.
Read More
Migden Reviews Updated Data for PD-1 Agents in Case Review of cSCC
September 20th 2019Michael R. Migden, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about responses in patients with cutaneous squamous cell carcinoma to immunotherapy treatment.
Read More
Expert Suggests Novel Approaches To Improve CAR Therapies in ALL
September 13th 2019To improve the efficacy of chimeric antigen receptor T-cell therapies, Nirali N. Shah, MD, MHSc, suggested including new constructs that target more than 1 antigen in patients with acute lymphoblastic leukemia, during a presentation at the 2019 SOHO Annual Meeting.<br />
Read More
Update Shows Long-Term Benefit With Dabrafenib Plus Trametinib in Advanced Melanoma in COMBI Trials
September 11th 2019In a recent review of the 5-year outcomes from the COMBI-d and COMBI-v trials published in the New England Journal of Medicine, investigators saw long-term benefit with the use of dabrafenib plus trametinib as first-line treatment in about one-third of patients with unresectable or metastatic melanoma and BRAF V600E or V600K mutations.
Read More
Combination Regimen Options Under Investigation in Melanoma
September 5th 2019Keith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.
Watch
Expert Highlights Key Studies Revolutionizing the Melanoma Treatment Landscape
August 30th 2019In an interview with Targeted Oncology, Shailender Bhatia, MD, highlighted the key takeaways from the 5 abstracts he found most significant at the 2019 ASCO meeting for the treatment of patients with melanoma.
Read More
Neelapu Discusses Toxicities Associated With CAR T Cells in Large B-Cell Lymphomas
August 29th 2019In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.
Read More
Nivolumab Plus Ipilimumab Shows Long-Term Survival in Patients With Advanced Melanoma
August 29th 2019In an interview with <em>Targeted Oncology</em>, Michael Atkins, MD, discussed the latest follow-up data from the combination of nivolumab and ipilimumab across 2 trials and next steps in the research with this combination for patients with advanced melanoma.
Read More
Molecular Subtypes of Merkel Cell Carcinoma Identified in Large Genomic Study
August 14th 2019In the largest genomic study of Merkel cell carcinoma tumors to date, investigators identified 2 distinct molecular subgroups, an ultraviolet light–driven subtype and a viral-driven subtype, which matched with tumor mutational burden classifications.
Read More
CAR T-Cell Therapy Poised to Become Routine Care in CLL
August 13th 2019The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements.
Read More
Four-Year Follow-Up Data Confirm Durable Responses With CAR T-Cell Therapy in B-Cell Lymphomas
August 7th 2019In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
Read More
Phase III Trial Investigating Adjuvant Cemiplimab in High-Risk CSCC
August 6th 2019A phase III clinical trial has begun to investigate the use of cemiplimab as an adjuvant treatment after surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma.<br />
Read More
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLL
August 2nd 2019In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More